-+ 0.00%
-+ 0.00%
-+ 0.00%

BlossomHill Plans Pivotal Phase 2 Trial of BH-30643 in Lung Cancer for Q1 2027

PUBT·11/09/2026 12:11:05
Listen to the news
BlossomHill Plans Pivotal Phase 2 Trial of BH-30643 in Lung Cancer for Q1 2027
  • BlossomHill Therapeutics plans to begin pivotal Phase 2 SOLARA-2 testing of BH-30643 in EGFR C797S-positive lung cancer in the first quarter of 2027.
  • The FDA aligned on a 50 mg twice-daily dose for the trial, which could support an accelerated approval application.
  • Enrollment targets approximately 150 patients previously treated with third-generation EGFR inhibitors, split equally between chemotherapy-naive and chemotherapy-pretreated groups.
  • Preliminary SOLARA results presented at ASCO and WCLC in 2026 showed promising antitumor activity, including in patients with brain metastases.
  • Additional results planned for 2027 medical meetings include response durability updates and initial chemotherapy-combination data.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blossomhill Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONEFULLFEED9873055) on November 09, 2026, and is solely responsible for the information contained therein.